Investment, Funding & Disinvestments

Under the collaboration, the companies will evaluate Helicons both as standalone therapies and as payloads linked to Regeneron antibodies.

This agreement also grants Boston Scientific an exclusive option to acquire the TAVR programme, subject to additional payments and to clinical and regulatory milestones.

The facility is built to accommodate approximately 1,000 to 1,500 healthcare professionals each year, including consultants, specialists, and early-career doctors.

The JV combines Arna Pharma’s formulation development expertise and portfolio expansion strategy with Slate Run Pharmaceuticals’ established US commercial operations, regulatory capabilities, and supply chain infrastructure.

The initiative, implemented with the Ministry of Health in Ghana, arrives at a time when countries are increasingly adopting digital technologies to address complex health challenges such as climate-sensitive diseases and unequal access to care.

The launch coincides with the company’s 30th year of operations and reinforces its strategy of building an integrated healthcare system across Uganda.

Through this acquisition, the company strengthens its ability to support cell therapy developers with integrated manufacturing, processing, and cryopreservation services under a unified platform.

Isomorphic Labs plans to use the new capital to further develop and deploy its proprietary AI drug design engine, known as IsoDDE.

The acquisition will give Zydus access to Assertio’s commercial infrastructure in the US specialty pharmaceutical market, particularly in oncology supportive care and pain management therapies.

The approval applies to adolescents and adults weighing at least 35 kilograms who have haemophilia A with factor VIII inhibitors or haemophilia B with factor IX inhibitors.